Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.68 |
| ▸ | HPGDS | O60760 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL110012 | 1.00 | MEN1 (0.68) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13556323 | 0.90 | TRPA1 (0.69) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12723664 | 0.90 | TRPA1 (0.65) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15396458 | 0.89 | TRPA1 (0.69) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16272334 | 0.89 | TRPA1 (0.69) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL111095 | 0.88 | SMN1; SMN2 (0.74) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28809030 | 0.88 | TRPM2 (0.69) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16272299 | 0.88 | TRPA1 (0.63) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28809027 | 0.88 | TRPM2 (0.69) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15396755 | 0.87 | MMP1 (0.55) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140072584-A1 | NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES | LI, YINGJI (CN) | 2014-03-13 | — | — | US | claimed |
| EP-2649992-A1 | NEW PHARMACEUTIC USE OF BENZOIC AICD DERIVATIVES | Li, Xianliang (CN) | 2013-10-16 | — | — | EP | claimed |
| WO-2010071865-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | claimed |
| US-20100160351-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | claimed |
| EP-2173167-A2 | TREATMENT OF NEUROPATHIC PAIN | Nuon Therapeutics, Inc. (US) | 2010-04-14 | — | — | EP | claimed |
| US-20100041756-A1 | METHOD OF MODULATING B CELL FUNCTIONING | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY & MEDICINE (GB) | 2010-02-18 | — | — | US | claimed |
| US-20090312422-A1 | METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME | EBERHARD-KARLS-UNIVERSITAET TUEBINGEN UNIVERSITAETSKLINIKUM | 2009-12-17 | — | — | US | claimed |
| US-20090197957-A1 | Methods and compositions for the treatment of pain | NUON THERAPEUTICS, INC. | 2009-08-06 | — | — | US | claimed |
| US-20090042987-A1 | TREATMENT OF NEUROPATHIC PAIN | NUON THERAPEUTICS INC. | 2009-02-12 | — | — | US | claimed |
| WO-2009008997-A2 | TREATMENT OF NEUROPATHIC PAIN | NUON THERAPEUTICS, INC. (US) | 2009-01-15 | — | — | WO | claimed |
| EP-1824469-A4 | A METHOD OF MODULATING B CELL FUNCTIONING | NUON THERAPEUTICS PTY LTD (AU) | 2008-07-30 | — | — | EP | claimed |
| US-20080103204-A1 | Method of modulating cellular activity and agents useful for same | EBERHARD-KARLS-UNIVERSITAT TUBINGEN (DE) | 2008-05-01 | — | — | US | claimed |
| EP-1845967-A4 | A METHOD OF MODULATING T CELL FUNCTIONING | UNIV LELAND STANFORD JUNIOR (US) | 2008-03-05 | — | — | EP | claimed |
| US-20080009519-A1 | METHOD OF MODULATING T CELL FUNCTIONING | ANGIOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2008-01-10 | — | — | US | claimed |
| EP-1845967-A2 | A METHOD OF MODULATING T CELL FUNCTIONING | The Board of Trustees of Leland Stanford Junior University (US) | 2007-10-24 | — | — | EP | claimed |
| EP-1824469-A1 | A METHOD OF MODULATING B CELL FUNCTIONING | Angiogen Pharmaceuticals Pty. Ltd (AU) | 2007-08-29 | — | — | EP | claimed |
| WO-2006076580-A2 | A METHOD OF MODULATING T CELL FUNCTIONING | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2006-07-20 | — | — | WO | claimed |
| WO-2006053390-A1 | A METHOD OF MODULATING B CELL FUNCTIONING | ANGIOGEN PHARMACEUTICALS PTY. LTD. (AU) | 2006-05-26 | — | — | WO | claimed |
| US-20140072584-A1 | NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES | LI, YINGJI (CN) | 2014-03-13 | — | — | US | disclosed |
| WO-2006053390-A1 | A METHOD OF MODULATING B CELL FUNCTIONING | ANGIOGEN PHARMACEUTICALS PTY. LTD. (AU) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103204-A1 | Method of modulating cellular activity and agents useful for same | NLN, GAP43, CYBB | MEN1 3828/4885KMT2A 3579/4885NPC1 2749/4885 |
| US-20140072584-A1 | NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES | NFATC1, GABRA5, GABRA6 | MEN1 4643/4885KMT2A 2566/4885NPC1 1973/4885 |
| US-20100160351-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | XDH, SLC10A1, SLC10A6 | MEN1 1944/4885KMT2A 3365/4885NPC1 108/4885 |
| US-20080009519-A1 | METHOD OF MODULATING T CELL FUNCTIONING | IFNG, CD4, IDO1 | MEN1 3959/4885KMT2A 1759/4885NPC1 4332/4885 |
| US-20090197957-A1 | Methods and compositions for the treatment of pain | OPRL1, OPRK1, ACHE | MEN1 3723/4885KMT2A 1934/4885NPC1 1567/4885 |
| US-20090042987-A1 | TREATMENT OF NEUROPATHIC PAIN | OPRL1, GAP43, AANAT | MEN1 3473/4885KMT2A 1821/4885NPC1 1854/4885 |
| US-20100041756-A1 | METHOD OF MODULATING B CELL FUNCTIONING | KYNU, IDO1, IDO2 | MEN1 3204/4885KMT2A 1427/4885NPC1 4593/4885 |
| US-20090312422-A1 | METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME | NLN, GAP43, CYBB | MEN1 3828/4885KMT2A 3579/4885NPC1 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.